News
Incyte's PD-1 drug brings immunotherapy to anal cancer
Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer
News
Pathos AI's big $365m Series D, and other bio financings
Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.
News
MSD adds new indication for Welireg in rare tumours
MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.
News
AbbVie bags first approval for cancer ADC Emrelis
AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis.
Oncology
The mesenchymal stem cell’s superpower: Hacking the TME
What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
